Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Education
Role Competency Scale On Shared Decision-Making Nurses: Development And Psychometric Properties, Joseph D. Tariman Phd, Pamela Katz, Jessica Bishop-Royse Phd, Lisa Hartle Ms, Cns, Rn, Katharine Szubski Bsn, Rn, Toreend Enecio, Ima Garcia, Nadia Spawn Msn, Katherine Jones Masterton
Role Competency Scale On Shared Decision-Making Nurses: Development And Psychometric Properties, Joseph D. Tariman Phd, Pamela Katz, Jessica Bishop-Royse Phd, Lisa Hartle Ms, Cns, Rn, Katharine Szubski Bsn, Rn, Toreend Enecio, Ima Garcia, Nadia Spawn Msn, Katherine Jones Masterton
Joseph D Tariman PhD, RN, ANP-BC, FAAN
Objectives: This study aimed to develop a scale that can measure the role competency of oncology nurses during shared decision-making process. Methods: A total of 226 oncology nurses who actively provide direct care to patients from inpatient and outpatient oncology units in the Midwest and Pacific Northwest completed the online or mail survey. Exploratory factor analysis and parallel analysis showed the multidimensionality of the role competency scale on shared decision-making nurses. Results: The role competency scale on shared decision-making nurses revealed four dimensions: knowledge, attitudes, communication, and adaptability. The 22 items have excellent internal consistency with a Cronbach’s alpha of …
Biosimilars: Exploring The History, Science And Proogress, Joseph D. Tariman Phd
Biosimilars: Exploring The History, Science And Proogress, Joseph D. Tariman Phd
Joseph D Tariman PhD, RN, ANP-BC, FAAN
BACKGROUND: Biosimilars provide opportunities for improving healthcare access and outcomes and reducing overall healthcare costs for patients with cancer.
OBJECTIVES: The purpose of this article is to explore the history of biosimilars, regulatory pathways, and barriers to biosimilar approval. This article also aims to describe the patient and clinician barriers to biosimilars use and the progress that has been achieved since the first biosimilar approval in Europe in 2006 and in the United States in 2015.
METHODS: A literature search was conducted to retrieve articles that are highly relevant to the history of biosimilars development and regulatory pathways in the …